Biothera announced today the appointment of Ada H. Braun, M.D., Ph.D. as Chief Medical Officer responsible for the clinical and regulatory development of Imprime PGG®, the company’s Phase 3 cancer immunotherapy drug. Most recently, Dr. Braun was Executive Medical Director, Global Development, Hematology/Oncology at Amgen, Inc.
Help employers find you! Check out all the jobs and post your resume.
